Impact of Preoperative Suspension of Antiplatelet Therapy on Thrombotic Events Following Minimally Invasive Surgery for Abdominopelvic Cancer in Patients Using P2Y12 Inhibitors - Takeaways - MDSpire

Impact of Preoperative Suspension of Antiplatelet Therapy on Thrombotic Events Following Minimally Invasive Surgery for Abdominopelvic Cancer in Patients Using P2Y12 Inhibitors

  • By

  • Masashi Kubota

  • Satomi Yoshida

  • Takayuki Goto

  • Toshiki Fukasawa

  • Takayuki Anno

  • Gaku Fujiwara

  • Satoshi Toshiyama

  • Yoshihide Inayama

  • Takanori Yanai

  • Takayuki Sumiyoshi

  • Ryoichi Saito

  • Takashi Kobayashi

  • Koji Kawakami

  • January 16, 2026

  • 0 min

Share

  • 1

    Minimally invasive surgery (MIS) is increasingly used for treating abdominopelvic cancers due to its superior bleeding control.

  • 2

    P2Y12 inhibitors effectively prevent arterial thrombotic disease but increase the risk of hemorrhagic complications during surgery.

  • 3

    Current guidelines recommend a preoperative discontinuation of 5 days for clopidogrel and 7 days for prasugrel before high-bleeding-risk surgeries.

  • 4

    This study analyzes the impact of preoperative suspension versus maintenance of P2Y12 inhibitors on thrombotic events in MIS for cancer.

  • 5

    Data were collected from large Japanese hospital databases, focusing on patients undergoing radical surgery while on P2Y12 inhibitors.

Original Source(s)

Related Content